Adverse drug reaction profile of third-generation smallpox vaccines used in France during the 2022 monkeypox epidemic.
Fiche publication
Date publication
avril 2024
Journal
AIDS (London, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GILLET Pierre
Tous les auteurs :
Fresse A, Massy N, Fournier D, Pinel S, Beurrier M, Antoine ML, Petitpain N, Gillet P,
Lien Pubmed
Résumé
Due to the start of the monkeypox epidemic in 2022, we retrospectively analyzed the adverse drug reactions (ADRs) reported in France after monkeypox vaccinations with the third-generation smallpox vaccine. Ninety-eight cases, representing 172 ADRs, were reported. ADRs were mostly expected reactogenicity reactions occurring within days after the first dose of vaccine and having a quick favorable outcome. Unexpected facial palsy and vaccination failure are discussed.
Mots clés
Humans, Smallpox Vaccine, adverse effects, Mpox (monkeypox), epidemiology, Smallpox, epidemiology, Retrospective Studies, HIV Infections, Vaccination, adverse effects, France, epidemiology
Référence
AIDS. 2024 04 1;38(5):768-771